A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

NCT02230878 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-42847922 5 mg
DRUG: JNJ-42847922 10 mg
DRUG: JNJ-42847922 20 mg
DRUG: JNJ-42847922 40 mg
DRUG: Placebo

Sponsor

Janssen-Cilag International NV